Cell viability data demonstrated that olaparib, MMC and melphalan significantly decreased the viability of BRCA2 monoallelic and biallelic mutant gastrointestinal tumor cells at a concentration of 10 μM compared with that of BRCA2 wild-type tumor cells (Fig. S2b–S2e). The gene discussed is BRCA2; the disease is digestive system neoplasm.